Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Celularity Inc. (CELU:NASDAQ), powered by AI.
Celularity Inc. is currently trading at $0.71. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Celularity Inc. on Alpha Lenz.
View Celularity Inc.'s valuation metrics on Alpha Lenz.
“Celularity Inc.'s ROE is 627.7%. Explore profitability and growth together.”
Ask for details →Celularity Inc. is a biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for cancer and other serious diseases. The primary focus of the company is to harness the unique properties of postpartum placental cells to create advanced cellular therapies. These innovative solutions aim to address unmet medical needs in immuno-oncology, infectious diseases, and degenerative diseases. Celularity Inc. leverages its proprietary technology platform to produce these cellular products, which are designed to enhance immune responses and offer therapeutic benefits. The company's work significantly impacts the healthcare and biotechnology sectors, where there is a continuous demand for transformative treatments that can improve patient outcomes. Situated at the forefront of cell therapy development, Celularity Inc. plays a pivotal role in advancing the understanding and application of cellular medicine, making its contributions highly valuable within the financial markets and the broader biopharmaceutical landscape.
“Celularity Inc.'s ROE is 627.7%. Explore profitability and growth together.”
Ask for details →Celularity Inc. (ticker: CELU) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 123 employees.
The current price is $0.713 with a P/E ratio of -x and P/B of -x.
ROE is 627.65% and operating margin is -230.92%. Annual revenue is $27M.